ORPHA Orphazyme A/S

Change to Financial Calendar for 2023 and update regarding class action lawsuit in United States

Change to Financial Calendar for 2023 and update regarding class action lawsuit in United States

Company announcement                                                                                        

Orphazyme A/S

No. 01/2023   

Ole Maaløes Vej 3

DK-2200 Copenhagen N

Company Registration No. 32266355

Copenhagen, Denmark, April 17, 2023 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), announces that publication of its financial results for the full year ending December 31, 2022, previously expected April 19, 2023, are now expected to be published on April 25, 2023. Additional time is required to conclude the presentation of the financial statements. The updated financial calendar for 2023 is available on the Company’s website.

The Company also announces that the parties to the previously communicated class action lawsuit filed in the United States in July 2021 have reached an agreement in principle to settle the lawsuit in its entirety.  The parties are now undertaking to prepare mutually agreeable settlement documents, and the Court has stayed all proceedings in the lawsuit pending the filing of the parties’ settlement documents.  The parties currently anticipate that a motion seeking the Court’s preliminary approval of the settlement will be filed in May 2023 and that, if the Court grants preliminary approval, final court approval will be sought after members of the proposed settlement class have been afforded an opportunity to object to or opt out of the settlement.  The Company will provide an update when there has been final Court judgment with respect to the settlement.

For additional information, please contact

Orphazyme A/S

Anders Vadsholt, Chief Executive Officer and Chief Financial Officer

Forward-looking statement

This company announcement includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements about the expected timing for the Company’s annual report. The words “expect” and “anticipate” and variations of these words or similar words are intended to identifying forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control, including pursuant to regulatory or judicial intervention. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Attachment



EN
17/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orphazyme A/S

 PRESS RELEASE

Referat fra ekstraordinær generalforsamling

Referat fra ekstraordinær generalforsamling Selskabet har afholdt ekstraordinær generalforsamling den 21. oktober 2024 kl. 10:00 på selskabets adresse Lyskær 8A, 2730 Herlev med følgende dagsorden: Bestyrelsens forslag om ændring af formålBestyrelsens forslag om ændring af navnBestyrelsens forslag om skadesløsholdelse af bestyrelsesmedlemmer og direktionBestyrelsens forslag om valg af ny revisor BDOEventuelt Bestyrelsen havde i henhold til selskabets vedtægter pkt. 4.8 udpeget Jakob Have som dirigent for den ekstraordinære generalforsamling. Dirigenten konstaterede, at den ekstraordinære ...

 PRESS RELEASE

Bestyrelsesmedlemmers direktørers eller nærtstående personers handel m...

Bestyrelsesmedlemmers direktørers eller nærtstående personers handel med Orphazyme aktier Selskabsmeddelelse 32/2024                                                                                18. oktober 2024                                                                                                                                                                                                                                                      BESTYRELSESMEDLEMMERS, DIREKTØRERS ELLER NÆRTSTÅENDE PERSONERS HANDEL MED ORPHAZYME AKTIER Se venligst vedlagte. Vedhæftede fil...

 PRESS RELEASE

Bestyrelsesmedlemmers direktørers eller nærtstående personers handel m...

Bestyrelsesmedlemmers direktørers eller nærtstående personers handel med Orphazyme aktier._ Selskabsmeddelelse 29/2024                                                                                 7. oktober 2024                                                                                                                                                                                                                                                         BESTYRELSESMEDLEMMERS, DIREKTØRERS ELLER NÆRTSTÅENDE PERSONERS HANDEL MED ORPHAZYME AKTIER Se venligst vedlagte...

 PRESS RELEASE

BESTYRELSESMEDLEMMERS, DIREKTØRERS ELLER NÆRTSTÅENDE PERSONERS HANDEL ...

BESTYRELSESMEDLEMMERS, DIREKTØRERS ELLER NÆRTSTÅENDE PERSONERS HANDEL MED ORPHAZYME AKTIER Se venligst vedlagte. Vedhæftede filer

Orphazyme AS: 2 directors

Two Directors at Orphazyme AS bought 234 shares at between 1,123.414DKK and 1,191.688DKK. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch